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ABSTRACT (148/150 words) 
 
On-target resistance to next-generation TRK inhibitors in TRK fusion-positive cancers is largely 
uncharacterized. In patients with these tumors, we found that TRK xDFG mutations confer 
resistance to type I next-generation TRK inhibitors designed to maintain potency against several 
kinase domain mutations. Computational modeling and biochemical assays showed that TRKA 
G667 and TRKC G696 xDFG substitutions reduce drug binding by generating steric hindrance. 
Concurrently, these mutations stabilize the inactive (DFG-out) conformations of the kinases, 
thus sensitizing these kinases to type II TRK inhibitors. Consistently, type II inhibitors impede 
the growth and TRK-mediated signaling of xDFG-mutant isogenic and patient-derived models. 
Collectively, these data demonstrate that adaptive conformational resistance can be abrogated 
by shifting kinase engagement modes. Given the prior identification of paralogous xDFG 
resistance mutations in other oncogene-addicted cancers, these findings provide insights into 




SIGNIFICANCE (50/50 words) 
In TRK fusion-positive cancers, TRK xDFG substitutions represent a shared liability for type I 
TRK inhibitors. In contrast, they represent a potential biomarker of type II TRK inhibitor activity. 
As all currently available type II agents are multikinase inhibitors, rational drug design should 
focus on selective type II inhibitors creation. 
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Sequential tyrosine kinase inhibitor (TKI) therapy is an established strategy for cancers driven 
by an oncogenic kinase (1). Treatment is initiated with an early-generation TKI and, upon the 
acquisition of resistance, a next-generation TKI is employed. This paradigm is typified by fusion-
positive cancers for which rationally-designed next-generation TKIs (lorlatinib for ALK fusions; 
repotrectinib for ROS1 fusions) have been shown to re-establish disease control in the face of 
kinase domain mutation-mediated resistance to earlier-generation inhibitors (crizotinib, ceritinib 
or alectinib for ALK fusions; crizotinib or entrectinib for ROS1 fusions) (2-4). The design of these 
next-generation agents is informed by a wealth of information on mechanisms that drive 
resistance to early-generation therapy (5).  
 
Unfortunately, the dynamics that drive resistance to next-generation TKI therapy are more 
poorly characterized. In particular, while the evolutionary pressures of sequential TKI therapy 
propel the emergence of off-target/bypass tract-mediated resistance in select cancers (4,6), 
other cancers clearly acquire on-target resistance. On-target resistance mechanisms must 
induce structural changes in the kinase domain that ultimately impair the inhibitory effects of 
drug binding but simultaneously maintain kinase activity. Identifying and characterizing these 
mechanisms is an unmet need. 
 
TRK fusion-positive cancers provide a prototype for the study of persistent on-target resistance 
in the context of sequential TKI therapy across lineage climates (7). First-generation TRK 
inhibitors such as larotrectinib and entrectinib are approved by multiple regulatory agencies for 
the treatment of TRK fusion-positive adult and pediatric cancers in a tumor-agnostic fashion (8-
10). In response to first-generation therapy, many cancers will acquire kinase domain mutations 
that mediate resistance (8,11,12). Interestingly, these mutations result in amino acid 
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substitutions in conserved regions that are paralogous to kinase domain substitutions that 
mediate resistance in other fusion-positive cancers. For example, the solvent front substitutions 
TRKA G595R and TRKC G623R are paralogous to ALK G1202R and ROS1 G2032R (4). The 
2nd-generation TRK inhibitors selitrectinib (LOXO-195, a selective TRK inhibitor) and 
repotrectinib (TPX-0005, a multikinase TRK and ROS1 inhibitor) were designed to target many 
of these kinase domain mutations (13,14). Both drugs are in prospective trials and have shown 
clinical activity in TRK fusion-positive cancers with kinase domain mutation-mediated resistance 
to the 1st-generation agents larotrectinib or entrectinib.  
 
In this paper, we study how TRK xDFG mutations can mediate resistance to 2nd-generation TRK 
inhibitors. The xDFG residue maps immediately N-terminal to the DFG motif, an evolutionary 
conserved triad across most kinases whose orientation defines the conformational states 
adopted by kinases (15). In an active or DFG-in conformation, the aspartate (D) of this motif 
points towards the ATP binding site where it coordinates two Mg2+ ions.  In the inactive or DFG-
out state, the aromatic ring of the phenylalanine (F) residue flips by approximately 180°, moving 
the aspartate away from the ATP pocket with the consequent inhibition of catalytic activity (15). 
Small molecule kinase inhibitors that bind to the active conformation of kinases (i.e., 1st- and 
2nd-generation TRK inhibitors available in the clinic) are classified as type I inhibitors and are 
canonical ATP competitors. In addition to the ATP-binding pocket, type II inhibitors also occupy 
an adjacent allosteric site (commonly referred to as the “back pocket”) across the DFG motif; 
this back pocket is fully accessible only when the kinases are in the inactive conformation 
(16,17).  
 
Our study indicates that while TRK xDFG substitutions represent a shared liability for type I TRK 
inhibitors, these substitutions represent a potential biomarker of sensitivity for type II multikinase 
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inhibitors, drugs that bind to and stabilize the inactive conformations of TRK kinases and 
prevent their transition into the active state (17,18). 
RESULTS 
TRKA xDFG Mutations Emerge with Second-generation TRK Inhibitor Resistance. TRKA 
xDFG mutations resulting in G667 substitutions emerged in tumor DNA from patients with TRK 
fusion-positive cancers that progressed on 2nd-generation TRK inhibitor therapy (Figure 1). 
Patient 1, with a TPM3-NTRK1-fused, TRKA G595R-mutant sarcoma, was treated with 
selitrectinib with limited durability. After 4 months of therapy, tumor sequencing at progression 
(pre- and post-selitrectinib samples obtained from the same lung metastasis site) showed the 
acquisition of a TRKA G667C (29% allele frequency) mutation and loss of the TRKA G595R 
solvent front mutation (Figure 1A). Patient 2, with a LMNA-NTRK1-fused, TRKA G595R-mutant 
breast cancer, experienced a mixed response with selitrectinib. Cell-free DNA (cfDNA) collected 
after two months on therapy (coinciding with rapid liver metastases growth) similarly 
demonstrated TRKA G667C acquisition and TRKA G595R loss (Figure 1B). For Patient 1, 
TRKA G667C was found in the pre-treatment sample at 0.3% (2/544 reads). Although the same 
analysis was not possible for Patient 2, these results suggest that pre-existing TRKA G667C-
containing clones may have been selected by selitrectinib treatment. 
 
Patient 3 with an LMNA-NTRK1-fused, TRKA G595R-mutant colorectal cancer (CRC) received 
selitrectinib and developed resistance after 11 months of treatment. Sequencing of the resistant 
tumor revealed a new TRKA G667A mutation and persistence of the TRKA G595R mutation 
(Figure 1C). These mutations were clonal, had similar allele frequencies (33% and 27%, 
respectively), and were found on the same allele in cis by RNA sequencing (Supplementary 
Figure S1A). In parallel, in a TRKA G595R-mutant CRC cell line that became resistant to 
repotrectinib after continuous drug exposure, we found that a new TRKA G667C substitution 
was acquired while TRKA G595R was retained (Figure 1D). The allele frequencies of these 
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mutations were similar (63% and 65%, respectively) and RNA sequencing confirmed their 
occurrence in cis (Supplementary Figure S1B). Proliferation assays and Western blot 
experiments conducted on this cell line showed that 2nd-generation drugs failed to inhibit cell 
growth and TRK activated downstream signaling, confirming its resistant phenotype (Figure 1E, 
F). 
 
Given that TRKA G667 mutations were identified at the time of progression on 2nd-generation 
TRK inhibitor therapy, we sought to evaluate whether these substitutions also confer primary 
resistance to the same agents. We identified two patients (Patients 4 and 5) who progressed on 
larotrectinib by acquiring TRKA G667 mutations. Patient 4 with a TPR-NTRK1-positive non-
small cell lung cancer had a partial response (PR) on larotrectinib. Sequencing of cfDNA at 
progression identified the emergence of TRKA G667S. Unfortunately, intrinsic resistance to 
selitrectinib was observed (received only 2 months of therapy; Supplementary Figure S2A). 
Patient 5, with a TPM3-NTRK1 positive thyroid cancer, initially responded to larotrectinib and 
sequencing of the cfDNA at progression identified multiple emergent TRKA kinase mutations, 
including TRKA G667C and TRKA G667S. Similar to Patient 4, Patient 5 did not respond to 
selitrectinib (Supplementary Figure S2B). Together, these clinical and preclinical findings 
suggest that TRKA xDFG substitutions (as single or compound mutations) limit sensitivity to 2nd-
generation TRK inhibitors. 
 
TRKA xDFG Substitutions Compromise 2nd-generation TRK Inhibitor Binding. To 
investigate the mechanism by which TRKA G667 substitutions confer resistance to 2nd-
generation TRK inhibitors, we performed in silico molecular modeling combined with molecular 
dynamics (MD) simulations. Both 2nd-generation TRK inhibitors currently in clinical testing, 
selitrectinib and repotrectinib, bind to the ATP binding pocket of TRKA with an orientation that 
places their rigid fluoropyrimidine-containing aromatic moieties in close proximity to the glycine 
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667 residue. As such, substitution of the small glycine residue with any other amino acid, even 
those that have side chains with minimal additional bulk (e.g. the methyl side chain for alanine 
or the thiol side chain for cysteine), results in steric hindrance and compromises selitrectinib and 
repotrectinib binding (Figure 2A). Consistently, binding free energy calculations indicate that 
both selitrectinib and repotrectinib lose affinity for TRKA xDFG mutants when compared with 
wild type TRKA (Supplementary Figure S3A). 
 
To confirm that TRKA G667 mutations result in a reduced activity of 2nd-generation TRK 
inhibitors, we performed in vitro kinase assays using TRKA wild type (WT), TRKA G595R-
solvent-front-mutant and TRKA G667-mutant kinases in the presence of increasing 
concentrations of selitrectinib or repotrectinib. Assays conducted on single (TRKA G667C) and 
double xDFG mutants (TRKA G595R/G667A and TRKA G595R/G667C) showed that the 
calculated IC50 for selitrectinib was 429.7- to 8514.3-fold higher compared to the IC50 obtained 
against the TRKA WT and 12.3 to 238.4-fold higher compared to the IC50 obtained against the 
selitrectinib-sensitive TRKA G595R solvent front mutant (Figure 2B). Similarly, the calculated 
IC50 for repotrectinib against TRKA xDFG mutants were 59.1- to 1863.6-fold higher compared to 
the IC50 obtained with the TRKA WT and 2.1- to 66.1-fold higher than IC50 calculated for the 
repotrectinib-sensitive TRKA G595R solvent front mutant (Figure 2B). Together, these data 
indicate that TRKA xDFG mutations limit the sensitivity to selitrectinib and repotrectinib through 
impaired drug binding. 
 
Type II TRK Inhibitors Preferentially Bind to and Inhibit TRKA, TRKC and ROS1 xDFG 
Mutants. Existing data suggest that multikinase type II inhibitors can bind TRKA carrying the 
G667C substitution (19,20). Therefore, we modeled TRKA xDFG and solvent front mutants in 
complex with three type II inhibitors: cabozantinib, foretinib and ponatinib (21,22). Molecular 
dynamics simulations and binding free energy calculations suggest that type II drugs can 
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potentially bind the solvent front as well as all the xDFG single and double mutant proteins as 
the resultant substitutions are not predicted to generate steric hindrance (Figure 3A and 
Supplementary Figure S3B). Surprisingly, however, in vitro kinase assays showed that IC50 
calculated for cabozantinib, foretinib and ponatinib for TRKA xDFG single and double mutants 
were 3.4- to 579.3-fold lower than IC50 for the solvent front mutant and up to 72.3-fold lower 
than IC50 for TRKA wild type (Figure 3B-D), indicating that the presence of a TRKA xDFG 
substitution is sufficient to sensitize TRKA kinases to type II inhibitors. Interestingly, mutants 
with the Gly to Cys substitution in the xDFG codon of the TRKA kinases were found to be more 
sensitive to type II inhibitors than the double mutant harboring the Gly to Ala substitution, 
suggesting allele-specific sensitivity. Together, these results indicate that type II multikinase 
inhibitors may have higher affinity than type I 2nd-generation TRK specific inhibitors for TRKA 
xDFG mutants.  
 
To test this hypothesis, we performed in vitro microscale thermophoresis to directly measure the 
binding affinity of cabozantinib/foretinib versus selitrectinib for the TRKA G667C-mutant kinase. 
Our results show that the dissociation constants (Kds) for cabozantinib and foretinib were 8.84- 
and 10.74-fold lower than the Kd determined for selitrectinib, respectively (Figure 3E). This 
suggests that TRKA xDFG substitutions may induce preferential adoption of the DFG-out 
conformation and increase type II inhibitor binding affinity, similar to data previously reported for 
the ERK2 kinase modified to harbor xDFG substitutions in mutagenesis-based assays (23). We 
then carried out all atom MD simulations of apo TRKA in its WT and mutant states. This 
analysis showed that, in the inactive conformation of the WT TRKA kinase, the xDFG residue 
(Gly667) is predicted to interact with the side chain of His648 of the His-Arg-Asp (HRD) motif 
that precedes the activation loop. Due to the flexibility of the Gly667 residue, this interaction is 
predicted to be weak, facilitating the transition of the TRKA WT kinase from the inactive to the 
active conformation (Figure 3F, upper panel). When Gly667 is substituted with a Cys, the 
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presence of the bulky side chain group at this position is predicted to bring the carbonyl 
backbone of Cys667 and the side chain of the His648 into close proximity, thus stabilizing their 
interaction and favoring the inactive conformation. The distance between Gly667 and His648 in 
the WT TRKA in the inactive state is about 8 Angstroms but reduces to approximately 3 
Angstroms when the Gly667 is substituted with the bulkier Cys (Figure 3F lower panel and 
Supplementary Figure S3C). According to this model, the reduced flexibility of the Cys667-
His648 complex would increase the propensity of the mutated kinase to be stabilized in the 
inactive state (DFG-out), thus increasing the ability of cabozantinib and foretinib to bind the 
hydrophobic allosteric back pocket.  
 
To study the generalizability of our findings, we next evaluated whether xDFG mutations also 
confer sensitivity to type II drugs in another member of the TRK kinases, TRKC, and in ROS1, a 
kinase that shares 39% identity with TRKA and can also form oncogenic fusions (24). In vitro 
radiometric assays showed that TRKC xDFG (G696A and G696C) and ROS1 xDFG (G2101A 
and G2101C) mutant recombinant kinases are exquisitely sensitive to type II inhibitors, drugs 
found to be less active against TRKC and ROS1 wild type or TRKC and ROS1 solvent front 
(G623R and G2032R, respectively) mutant kinases (Supplementary Figure S4A, B).  
 
Consistent with the biochemical assays, while cabozantinib slightly inhibited TRKC or ROS1 
wild type kinase phosphorylation when transfected in HEK293T cells, it markedly inhibited 
TRKC or ROS1 mediated signaling when the same cells were transfected with the Gly to Cys 
xDFG TRKC or ROS1 mutants (Supplementary Figure S4C, D). Atom MD simulations of apo 
TRKC and ROS1 in their WT and mutant states also showed that the distance between the 
TRKC or ROS1 xDFG residue and the His677/1247 of the HDR motifs reduced about 3-fold 
when the Gly 696/2101 are substituted with the bulkier Cys (Supplementary Figure S4E, F). 
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This is predicted to stabilize the mutated kinases in the DFG-out conformation, thus sensitizing 
to type II agents.  
 
Since our data suggested that xDFG mutations induce structural changes that sensitize to type 
II drugs in multiple related kinases, we evaluated the prevalence of these mutations in the MSK-
IMPACT cohort in 13 kinases that share high sequence identity with TRKA/B/C. Our analysis 
shows that xDFG mutations are recurrently found in several kinases including RET, ALK, ROS1, 
EGFR and ERBB2 in tumors of various histology, thus broadening the potential clinical 
relevance of our findings (Supplementary Figure S4G).  
 
xDFG-Mutant Bcan-Ntrk1-Containing Mouse Gliomas Respond to Type II TRK Inhibitors. 
To test whether type II TRK inhibitors are effective against TRKA xDFG mutants in cell models, 
we used clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 to knock-in 
TRKA solvent front and xDFG single and double mutations in tumor cells derived from a Bcan-
Ntrk1-driven mouse model of glioma (Supplementary Figure S5; (25)). Single and double 
mutant clones bearing the Trka G598R solvent front mutation, the mouse orthologue to human 
TRKA G595R, and/or the Trka G670C/A xDFG substitutions, orthologues to human TRKA 
G667C/A, (Figures 4A-D, Supplementary Figure S6A-J) were tested for their sensitivity to 
type I and type II TRK inhibitors. Consistent with our in vitro radiometric assays, Bcan-Ntrk1, 
Trka xDFG single and double (xDFG and solvent front) mutant cells were resistant to 
selitrectinib and repotrectinib, but sensitive to cabozantinib, foretinib, and ponatinib (Figure 4E). 
Furthermore, type II drugs efficiently inhibited Trka-mediated downstream signaling of Trka 
single and double xDFG-mutant clones (Figure 4F). Similar results were obtained with two 
independent clones for each mutant (Supplementary Figure S7A, B).  
 
Research. 
on October 4, 2020. © 2020 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 1, 2020; DOI: 10.1158/2159-8290.CD-20-0571 
12 
 
Resistance to selitrectinib and repotrectinib was reduced in xDFG mutants harboring the Gly to 
Ala substitution (Trka double-mutant clones). These clones also displayed an intermediate 
sensitivity to cabozantinib, foretinib and ponatinib, thus paralleling the kinase assay data 
obtained with this mutant. To further characterize the effect that the TRKA G595R/G667A 
double mutant has on drug response, we treated mouse glioma cells harboring this double 
mutation with increasing concentrations of selitrectinib or cabozantinib for 30 minutes or 24 
hours and evaluated changes in the phosphorylation status of Trka. Our results showed that, 
while both drugs were highly effective in inhibiting Trka phosphorylation after 30 minutes of 
exposure, only cabozantinib maintained efficacy after 24 hours (Supplementary Figure S7C). 
These data indicate that cabozantinib results in more durable pathway inhibition when 
compared to selitrectinib in the Trka G598R/G670A double mutant, suggesting that cabozantinib 
may be more effective than selitrectinib in a chronic regimen or an in vivo setting.  
 
To obtain mechanistic insights that could explain why type II inhibitors have increased activity 
specifically for TRK xDFG mutants, we set to investigate the biochemical properties of Trka 
xDFG mutant glioma cells. Proliferation and colonies formation assays showed no differences in 
growth rate or oncogenic potential between cells harboring only the Bcan-Ntrk1 fusion and cells 
that also bear the Trka G670C mutation. Cells harboring the solvent front G598R single 
mutation and cells with the double mutations, Trka G598R/G670A and Trka G598R/G670C 
were instead significantly slower and significantly less oncogenic than cells harboring the fusion 
only or cells also bearing the Trka G670C (Supplementary Figure S7D, E). Together, these 
data indicate that the increased sensitivity that xDFG single and double mutant cells show for 
type II inhibitors when compared to cells harboring the fusion only or with the Trka G598R 
solvent front mutation is not the result of differences in the proliferation rate or the oncogenic 
properties of these mutants.  
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We then tested the antitumor activity of type II drugs in Bcan-Ntrk1, Trka xDFG-mutant cells 
injected intracranially into immunocompromised mice. One week after injection, we randomized 
mice into two groups and performed brain magnetic resonance imaging (MRI). One group (n=3) 
was treated with vehicle and the other group (n=4) with cabozantinib. We chose cabozantinib as 
a representative type II TRK inhibitor because of its ability to cross the blood-brain-barrier (BBB) 
(26). MRI scans after 7 days of treatment showed that, while the tumor size of vehicle-treated 
mice increased up to 10-fold (accompanied by cerebral edema), cabozantinib prevented tumor 
growth (Figure 4G, H). Accordingly, mice in the cabozantinib group survived significantly longer 
than mice in the control group (median of 8 vs 22 days, respectively; P=0.0143; Figure 4I).  
 
Type II TRK Inhibitors Overcome xDFG-mediated Resistance in Patient-derived Models. 
We next tested the antitumor activity of type II inhibitors in patient-derived models that became 
resistant to 2nd-generation TRK inhibitors by acquiring TRKA xDFG mutations. Cell proliferation 
assays showed that these agents are highly active in inhibiting cell growth of the LMNA-NTRK1, 
TRKA G595R/G667C repotrectinib-resistant cell line (described in Figure 1D-F) obtained 
following chronic drug exposure, while they are significantly less effective against the LMNA-
NTRK1, TRKA G595R parental counterpart (Figure 5A). In agreement with this phenotype, type 
II but not type I drugs fully inhibited TRKA downstream signaling in this cell model (Figure 5B).  
 
To confirm that the activity of the type II multikinase inhibitors against the double mutant cell line 
is the result of the specific inhibition of TRKA and not other targets, we tested the effects of 
crizotinib (MET inhibitor) and axitinib (VEGFR inhibitor) on cell viability and signaling. Results 
showed that only type II TRK inhibitors can induce cell death and inhibit TRKA-mediated 
signaling in the LMNA-NTRK1, TRKA G595R/G667C cell line (Supplementary Figure S8A, B). 
Similarly, xenografts derived from this cell line demonstrated that cabozantinib treatment was 
sufficient to inhibit tumor growth (Figure 5C).  
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Lastly, we tested the efficacy of this type II inhibitor in patient-derived xenografts (PDXs) 
established from the selitrectinib-resistant tumors of Patient 1 (the TPM3-NTRK1, TRKA G667C 
sarcoma) and Patient 3 (the LMNA-NTRK1, TRKA G595R/G667A CRC). Patient 1-derived 
tumors treated with cabozantinib achieved a complete and durable (3 months) response (Figure 
5D), while durable (2 months) disease control was observed in tumors derived from Patient 3 
(Figure 5E). Taken together, these data indicate that type II TRK inhibitors can overcome 
acquired resistance to 2nd-generation type I inhibitors mediated by the acquisition of xDFG 
mutations.    
 
DISCUSSION 
The emergence of on-target mutations that predispose oncogenic kinases to switch 
conformational states is a largely underappreciated mechanism of targeted therapy resistance. 
Here, we demonstrate that xDFG mutations are recurrently identified in patients and preclinical 
models from diverse histologies of TRK fusion-positive cancers refractory to 2nd-generation TRK 
inhibitor therapy. Clones with xDFG mutations can either be present de novo or be acquired 
with TKI therapy. 
 
Structural modeling and biochemical studies reveal that xDFG substitutions not only limit TRK 
inhibitor binding by generating steric hindrance but result in preferential adoption of the inactive 
DFG-out conformation by TRK kinases. Our experiments show that neither differences in growth 
rate nor the oncogenic potential of these xDFG mutants can explain DFG-out conformation 
adoption. We thus posit that xDFG substitutions induce structural changes that delay the 
transition of these kinase molecules from the DFG-out to the DFG-in conformation. This in turn, 
could increase the sensitivity of these mutants for type II inhibitors, drugs that specifically 
engage the DFG-out kinase state (Figure 6). This highlights that genomic interrogation alone 
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across fusion-positive cancers may be insufficient to understand the complex steric and 
conformational changes that govern drug resistance and sensitivity.  
 
It is important to recognize several factors. First, the crystal structures of type II inhibitors have 
yet to be complexed with TRK kinases to confirm type II binding. We likewise cannot rule out 
that these drugs bind to TRK via mechanisms beyond simple type II engagement. Second, not 
all xDFG substitutions are created equal; the size and charge of the substituted amino acid may 
induce differential phenotypes. For example, we found that Trka G670C-containing models 
harbored more resistance compared to TrkA G670A-containing models. The larger size of the 
cysteine (compared to alanine) and the partial negative charge on its sulphur atom may result in 
more steric hindrance and repulsion of the negatively charged fluoro-containing aromatic groups 
of the 2nd-generation TRK inhibitors, selitrectinib and repotrectinib. It is thus possible that GA 
xDFG substitution-containing cancers could respond initially to therapy, but with less durability 
compared to cancers harboring other on-target resistance mechanisms. 
 
xDFG mutations were initially identified as acquired resistance mechanisms to 1st-generation 
type I TRK inhibitors (8,12). Second-generation TKIs were thus designed to maintain activity 
against these and other more common resistance mutations. A primary design parameter of 
these small macrocyclic agents was the ability to abrogate steric hindrance resulting from 
solvent front and gatekeeper residue substitutions. Although second-generation TKIs were 
effective against many of these resistance mutations, these drugs were still designed as type I 
inhibitors. As such, these agents were not poised to avoid the penalties of structural shifts into 
the inactive conformation. Our work thus exposes an occult liability that was not predicted by 
initial experiments and highlights the inability of 2nd-generation type I TKIs to overcome all forms 
of on-target resistance.  
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These observations are potentially applicable to other oncogenic kinases. We demonstrate, for 
example, that xDFG substitutions not only occur across other kinases known to be involved in 
recurrent gene fusions but confer sensitivity to type II inhibitors in the context of ROS1 fusions. 
It should be noted that adaptive conformational resistance engendered by altering the relative 
proportion of active or inactive kinase pools can occur in either direction. In BCR-ABL-
containing chronic myelogenous leukemia, resistance mutations to 1st-generation TKI therapy 
with the type II TKI imatinib result in a preferential shift towards an active DFG-in conformation 
(27), the opposite of what is observed in TRK xDFG resistance. The emergence of mutations 
that induce conformational shifts has also been reported in EGFR (28), MET (29), KIT (30), RET 
(31), and ROS1-driven cancers (32).   
 
We show that type II inhibitors overcome xDFG resistance by binding the preferred inactive 
conformation of these mutant kinases. Although several TKIs are known to engage kinases in 
an inactive conformation, the vast majority of these agents (e.g. cabozantinib/foretinib) are 
repurposed multikinase inhibitors that were not intentionally designed to inhibit select targets 
(33). Therefore, they are characterized by substantial off-target inhibition and consequently a 
high frequency of side-effects and poor plasma exposures (34). In addition, these agents 
represent a minority of TKIs that are available in the clinic as most targeted therapies that are 
either approved (i.e. osimertinib, alectinib, brigatinib, lorlatinib, entrectinib) or in trials are type I 
inhibitors (35). Rational drug design should thus move towards the development of selective 
type II kinase inhibitors. While this can be challenging, particularly considering the heterogeneity 
of mutations that might be amenable to type II kinase inhibition, methods to test the affinity of 
candidate TKIs against multiple mutation variants have already been reported (36). 
 
In conclusion, our study uncovers a molecular switch induced by xDFG mutations that limits the 
sensitivity to type I kinase inhibitors. This occurs via the generation of steric hindrance and the 
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induction of conformational changes that favor the inactive DFG-out kinase state. This same 
switch, in turn, sensitizes these mutant kinases to type II inhibitors that effectively engage the 
inactive conformation. Ultimately, a combination of selective type I and type II inhibitors might 





Patients. Patients were treated with TRK inhibitors as part of prospective IRB-approved 
research protocols or expanded access protocols. All patients provided written informed consent 
for genomic sequencing of tumor and cfDNA, and review of medical records for detailed 
demographic, pathologic, and clinical data and for publication of this information as part of an 
institutional IRB-approved research protocol (MSKCC; NCT01775072). Research protocols for 
tumor collection and analysis were approved by the ethical committees of MSKCC.  
 
Compounds. Larotrectinib and selitrectinib were obtained from Loxo Oncology. Repotrectinib 
was purchased from Selleckchem. Cabozantinib, foretinib, ponatinib, crizotinib and axitinib were 
purchased from MedChem Express. All drugs were dissolved in DMSO to yield 10mM stocks 
and stored at -20℃.  
 
Targeted Tumor Sequencing. DNA from formalin-fixed paraffin-embedded tissue and matched 
germline DNA underwent targeted next-generation sequencing assay using (MSK-IMPACT; 
(37)). In brief, this assay uses a hybridization-based exon capture designed to capture all 
protein-coding exons and select introns of oncogenes, tumor-suppressor genes and key 
members of pathways that may be actionable by targeted therapies. In this study, either 410 or 
468 key cancer-associated genes were analyzed. Sequencing data were analyzed as previously 
described to identify somatic single-nucleotide variants, small insertions and deletions, copy 
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number alterations and structural rearrangements (38). In addition, hotspot alterations were 
identified using an adaptation of a previously described method (39) applied to a cohort of 
24,592 sequenced human cancers (40). 
 
Targeted Plasma Sequencing. Cell-free DNA (cfDNA) was extracted from all plasma samples 
and sequenced using a custom, ultra-deep coverage next-generation sequencing panel (MSK-
ACCESS). The custom assay includes key exons and domains of 129 and introns of 10 genes 
harboring recurrent breakpoints and uses duplex unique molecular identifiers (UMIs) and dual 
index barcodes to minimize background sequencing errors and sample-to-sample 
contamination. Sequencing data were analyzed using a custom bioinformatics pipeline that 
trims the UMIs, aligns the processed reads to the human genome, collapses PCR replicates into 
consensus sequences, and re-aligns the error-suppressed consensus reads. Consensus reads 
with representation from both strands of the original cfDNA duplex were used for de novo 
variant calling using VarDict (v1.5.1). Mutation calling required at least 1 collapsed read at a 
known cancer hotspot site or at least 3 collapsed reads at non-hotspot sites. All samples were 
sequenced to an average depth of approximately 20,000X coverage. Somatic mutations were 
identified and quantified as variant allele frequencies. Copy number alterations were identified 
across all samples using a previously described method (38). NTRK fusions were identified and 
quantified using Manta (v1.5.0). All samples were manually reviewed to identify NTRK fusions. 
Variants were called against an unmatched healthy plasma donor to identify any specimen type-
related artifacts. Mutations called at silent, intronic, and intergenic loci were removed. 
 
Structure Preparation. The structures of the apo forms of TRKA in its inactive state and of 
TRKA in its active state were generated using the available crystal structures. A crystal structure 
of apo TRKA in its inactive state (PDB: 4F0I) is available. The structure of the active form of apo 
TRKA was generated from the crystal structure of TRKA complexed to a ligand (PDB: 4YNE) by 
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removing the ligand. The 3D structures of the drug molecules larotrectinib, selitrectinib and 
repotrectinib were built using Maestro and minimized using the Macromodel module employing 
the OPLS-2005 force field (41) in Schrodinger 9.0.  All the drug molecules were then prepared 
with Ligprep that generates low energy tautomers and enumerates realistic protonation states at 
physiological pH. The prepared inhibitors were docked into the ATP binding pocket of the apo 
forms of TRKA kinase generated above using Glide (42). The docking was carried out under a 
constraint that a hydrogen bond is formed between the nitrogen atoms from the drug molecules 
and the backbone amide nitrogen of Met592 in TRKA; this was imposed based on the 
observation of such a hydrogen bond in the crystal structures of the ROS1 kinase complexed to 
Ent (Ent is a drug very similar to the drugs considered here; PDB 5KVT)  and of TRKA in its 
active state complexed to a ligand (also very similar to the drugs that are being studied here; 
PDB 4YNE). A box of size 10 x 10 x 10 Ǻ for molecular docking, centered on the ATP binding 
site residues of TRKA in its active state was used to define the search space of each docked 
drug molecule.  For the grid generation, the default Glide settings were used. The docked 
conformation of each ligand was evaluated using the Glide Extra Precision (XP) scoring 
function. The structural models of the drug molecules foretinib and ponatinib complexed to the 
inactive states of TRKA were generated using the co-crystal structures of foretinib bound to the 
inactive state of MET kinase (~39% identity to TRKA; PDB 6SD9) and of ponatinib bound to the 
inactive state of FGFR4 kinase (~41% identity to TRKA; PDB 4TYI). Both these complex 
structures were superimposed onto the structure of the inactive state of TRKA and the 
corresponding complexes of TRKA with foretinib and ponatinib generated. The structural model 
of cabozantinib complexed to the inactive state of TRKA was generated by modifying foretinib in 
its complexes with TRKA.  
Structural models of the apo forms and complexes of the mutant kinases in both active and 
inactive forms (G595R, G667C, G667A, G667S, G595R/G667C, G595R/G667A) with the 6 drug 
molecules (larotrectinib, selitrectinib, repotrectinib, cabozantinib, foretinib, ponatinib) were 
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modelled using the corresponding structures of the wild type kinases using the prime module 
(the sidechain orientations of the mutations are optimized) from the Schrodinger software. All 
the structural models were subsequently subjected to molecular dynamics (MD) simulations for 
further refinement.  
 
MD Simulations. MD simulations were carried out with the pmemd.cuda module of the program 
Amber18 (43). The partial charges and force field parameters for each drug molecule were 
generated using the Antechamber module in Amber.  All atom versions of the Amber14SB force 
field (ff14SB) (44) and the general Amber force field (GAFF) (45) were used to model the 
protein and the drug molecules respectively.  The Xleap module of Amber was used to prepare 
the systems for the MD simulations.  All the simulation systems were neutralized with 
appropriate numbers of counter ions.  Each neutralized system was solvated in an octahedral 
box with TIP3P (46) water molecules, leaving at least 10Å between the solute atoms and the 
borders of the box.  All MD simulations were carried out in explicit solvent at 300K.  During the 
simulations, the long-range electrostatic interactions were treated with the particle mesh Ewald 
(47) method using a real space cut off distance of 9Å. The Settle (48) algorithm was used to 
constrain bond vibrations involving hydrogen atoms, which allowed a time step of 2fs during the 
simulations. Solvent molecules and counter ions were initially relaxed using energy minimization 
with restraints on the protein and drug atoms. This was followed by unrestrained energy 
minimization to remove any steric clashes. Subsequently the system was gradually heated from 
0 to 300 K using MD simulations with positional restraints (force constant: 50 kcal mol-1 Å-2) on 
protein and drugs over a period of 0.25 ns allowing water molecules and ions to move freely.  
During an additional 0.25 ns, the positional restraints were gradually reduced followed by a 2 ns 
unrestrained MD simulation to equilibrate all the atoms. Finally, production MD simulations were 
carried out for 250ns in triplicates with conformations stored for every 10ps. Simulation 
trajectories were visualized using VMD (49) and figures were generated using PyMOL (50). A 
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summary of production of MD simulation details and time of simulations is reported in 
Supplementary Table S1A-C. 
 
In vitro Kinase Assays. Recombinant kinases were purchased by SignalChem Lifesciences 
Corporation (Richmond, BC, Canada). In vitro kinase assays were performed by Reaction 
Biology Corp. (Malvern, PA, US). Briefly, compounds (larotrectinib, selitrectinib, cabozantinib, 
foretinib and ponatinib) were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 2 uM 
in the presence of 10 uM ATP. Control compound Staurosporine was also tested. Two replicates for 
each dilution were performed. IC50 was calculated using GraphPad Prism version 8. 
 
Microscale Thermophoresis (MST). MST experiments were conducted by Reaction Biology 
Corp. (Malvern, PA, US). Selitrectinib concentrations ranged from 0.015 nM to 1000 nM (16 
doses) while cabozantinib and foretinib concentrations ranged from 0.003 nM to 100 nM (16 
doses). The concentration of the target (TRKA G667C) was kept constant at 5 nM. Two 
independent experiments were performed for each drug. Student T-test was used to calculate 
significant differences in Kds values. P<0.05 were considered statistically significant.  
 
Culture of Bcan-Ntrk1 Mouse Glioma Cells. All mouse p53-/- Bcan-Ntrk1 glioma cell lines 
were plated on laminin-coated dishes and cultured in Neurocult Stem Cell Basal Media with 
Proliferation Supplements (Stem Cell Technologies). The low-density seeding method was 
performed to isolate a monoclonal cell line harboring desired mutation from electroporated 
pooled population of mouse p53-/- Bcan-Ntrk1 glioma cells.  
 
CRISPR-Cas9 Mediated HDR. Cas9-gRNA ribonucleoprotein (RNP) complex and single-
stranded oligodeoxynucleotides (ssODNs) were used togenerate Trka mutations in Bcan-Ntrk1 
mouse glioma cells. We used a CRISPR-Cas9 mediated Homology-Directed Repair approach in 
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which cells were nucleofected with the Cas9-gRNA ribonucleoprotein complex together with 
single-stranded oligodeoxynucleotides (donor template sequences) that harbored the desired 
substitutions plus additional silent substitution designed to introduce a diagnostic restriction site.  
All crRNAs (Alt-R CRISPR-Cas9 crRNA) and ssODNs are synthesized by Integrated DNA 
Technologies and RNP complex was formed according to the manufacturer’s instructions. 
Sequences of crRNAs and ssODNs are found in Supplementary Table S2A. Briefly, gRNA 
was assembled by mixing equimolar amounts of crRNA and tracrRNA (Alt-R CRISPR-Cas9 
tracrRNA-ATTO-550) and heating to 95°C for 5 min. Cas9 (Alt-R S.p. Cas9 Nuclease V3) and 
gRNA were incubated for 10 min at room temperature to allow RNP formation. ssODNs and 
RNP complex were delivered into 1x10^5 mouse p53-/- Bcan-Ntrk1 glioma cells by 4D-Amaxa 
Nucleofector System (Lonza) using the Amaxa SF Cell Line Nucleofector X Kit S (Lonza) 
according to the manufacturer’s instructions. Cells were sorted based on ATTO-550 expression 
48 h post-nucleofection by the Flow Cytometry Core Facility at MSK.  
 
PCR and RT-PCR for Clone Selection. For PCR analysis of genomic DNA, cells were 
collected and genomic DNA was extracted by phenol:chloroform:isoamyl alcohol (Invitrogen). 
For RT-PCR, total RNA was isolated from cells using Trizol reagent (Invitrogen) and cDNA was 
generated using SuperScript III First-Strand Synthesis System (Invitrogen). The primers used in 
the various PCR reactions are provided in Supplementary Table S2B.  
 
CRISPR Sequencing. A ~ 200 bp region encompassing the modified locus targeted by 
CRISPR was PCR amplified from isolated genomic DNA and amplicon was gel purified (NEB). 
Each amplicon was sequenced to 75,000-100,000 reads sequencing. Reads were analyzed 
using CRISPResso by the MSKCC Integrated Genomics Operation. 
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Drug Screenings. Cell-Titer Glo-based assay: LMNA-NTRK1, TRKA G595R and LMNA-
NTRK1, TRKA G595R/G667C primary CRC cell lines or the isogenic mouse glioma cell lines 
were seeded in 96 well-plates (6,000 per well). The following day larotrectinib, selitrectinib, 
repotrectinib, cabozantinib, foretinib, ponatinib, crizotinib or axitinib (1:2 dilutions starting with a 
maximum concentration of 1000nM) was added. Cell-Titer Glo reagent was added 72 hours 
later and absorbance was read at 490nm according to the manufacturer protocol. Data are 
presented as % cell viability (mean±SD) normalized to the DMSO treated cells considered 
100% viable.  
 
Antibodies and Western Blots. Cells were seeded in 6 Well Plates (500000) per condition in 
full medium. The day after, cells were treated with 50nM of each compound for 30 minutes. 
Total protein lysates were extracted using RIPA buffer and quantified using BCA according to 
the manufacturer’s protocol. Lysates were separated using SDS-PAGE gels according to 
standard methods. Membranes were probed using the following antibodies: pan Trk clone 
A7H6R (92991S Cell Signaling Technology), phospho TrkA (Y674/675) clone C50F3 (4621S 
Cell Signaling Technology), phospho MEK1/2 (S217/221) clone 41G9 (9154S Cell Signaling 
Technology), total MEK1/2 (9122L Cell Signaling Technology), phospho p44/42 MAPK (Erk1/2; 
T202/Y204) clone D13.14.4E (4370S Cell Signaling Technology), total ERK1/2 (9102S Cell 
Signaling Technology), Phospho-Met (Tyr1234/1235) (3129S, clone 3D7 Cell Signaling 
Technology), total MET (8198S, clone D1C2 Cell Signaling Technology), V5 (A00623-100 
GeneScripts), phospho Tyrosine (4G10® Platinum, Anti-Phosphotyrosine 05-1050X Millipore), 
total ROS1 (3266S, clone 69D6, Cell Signaling Technology), phospho ROS1 (Tyr2274) (3078S 
Cell Signaling Technology) and β-actin clone 13E5 (4970S Cell Signaling Technology). 
 
Intracranial Injection. Four-to six months-old female NSG female mice were anaesthetized 
with ketamine/xylazine and treated with a pre-operative dose of buprenorphine prior to 
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craniotomy. 500,000 cells of mouse Bcan-Ntrk1 glioma cells harboring the Trka G670C 
substitution were delivered per animal via stereotactic intracranial injection targeting the 
neurogenic region of the right lateral ventricle. One week later, brain magnetic resonance 
imaging (MRI) was performed using a Bruker 4.7T Biospec scanner by the Animal Imaging Core 
Facility at Memorial Sloan Kettering Cancer Center. Images were visualized with the online 
miniPACS software. Mice were then randomized based on tumor size (calculated using ImageJ 
software) in vehicle (n=3) and cabozantinib (n=4) groups. Animals were treated with vehicle or 
cabozantinib daily (100mg/ml) via oral gavage. At day 7 of treatment, a second MRI was 
performed using the same scanner. Tumor size was quantified in both groups and data were 
then analysed using GraphPad 8.1.2. Treatments were continued until mice’ sacrifice to obtain 
survival curves. Mouse experiments were approved by MSKCC’s Institutional Animal Care and 
Use Committee. 
 
Patient-derived Primary Cell Lines. The entrectinib-resistant LMNA-NTRK1, TRKA G595R 
CRC cell line was obtained from Dr. Alberto Bardelli (Candiolo Cancer Institute, FPO, IRCCS, 
Turin, Italy). The LMNA-NTRK1, TRKA G595R/G667C cell line was established following 
chronic exposure of the LMNA-NTRK1, TRKA G595R to increasing concentrations of 
repotrectinib (ranging from 1 to 500nM) for five months. Cell lines were plated on petri dishes 
and cultured in DMEM/F12 + 10% FBS and 1% antibiotics. 
 
Xenografts and PDX Studies. Xenografts derived from the LMNA-NTRK1, TRKA 
G595R/TRKA G667C colorectal cancer primary cell line were generated by injecting 5 million of 
cells into the flank of six-weeks-old NSG female mice. When tumors reached 100 mm3 in size, 
mice were randomized and dosed orally with vehicle, repotrectinib (100mg/kg daily 5 days per 
week) or cabozantinib (100mg/Kg daily 5 days per week). PDXs derived from Patient 1 were 
randomized and dosed orally with vehicle, selitrectinib (100mg/kg BID 5 days per week) or 
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cabozantinib (100mg/Kg daily 5 days per week). PDXs derived from Patient 3 were randomized 
and dosed orally with vehicle, selitrectinib (100mg/kg BID 5 days per week), repotrectinib 
(100mg/kg daily 5 days per week) or cabozantinib (100mg/Kg daily 5 days per week). Tumors 
were measured twice weekly using calipers, and tumor volume was calculated using the formula 
length × width2 × 0.52. Body weight was also assessed twice weekly. Mice were cared for in 
accordance with guidelines approved by the MSK Institutional Animal Care and Use Committee 
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Figure 1. TRKA G667 Mutations Mediate Resistance to Second-generation TRK inhibitors 
in Patients and Preclinical Models 
Schematic showing the emergence of TRKA G667 mutations at progression on the 2nd-
generation TRK inhibitor selitrectinib in a TPM3-NTRK1, TRKA G595R mutated sarcoma patient 
(Patient 1; A), a LMNA-NTRK1, TRKA G595R mutated breast cancer patient (Patient 2; B) and 
a LMNA-NTRK1, TRKA G595R mutated colorectal cancer patient (CRC, Patient 3; C). Note that 
while in both Patient 1 and Patient 2 the TRKA G595R was not detected in the selitrectinib-
resistant sample, this mutation persisted in the selitrectinib-resistant tumor of Patient 3 (the 
allele frequencies of the TRKA G595R and the TRKA G667A mutations are indicated in 
parenthesis). PR: Partial Response; POD: Progression of Disease. All three patients were 
treated with a 1st-generation TRK inhibitor (entrectinib for Patient 1 and larotrectinib for Patient 2 
and 3) prior receiving selitrectinib and achieved a partial or complete response. At progression, 
sequencing of the resistant tumors revealed the presence of a TRKA G595R mutations in all 
three cases (A-C). (D) Schematic showing the emergence of a TRKA G667C mutation in a 
LMNA-NTRK1, TRKA G595R mutated primary CRC cell line that became resistant to the 2nd-
generation TRK inhibitor repotrectinb following chronic drug exposure. Cell-Titer-Glo-based 
proliferation assays (E) and Western blot analyses (F) confirming that the LMNA-NTRK1, TRKA 
G595R/G667C double mutant CRC cell line is resistant to both selitrectinib and repotrectinib.  
 
Figure 2. TRKA G667 Substitutions Generate Steric Hindrance that Compromises 
Selitrectinib and Repotrectinib Binding  
(A) Representative models from Molecular Dynamics (MD) simulations showing larotrectinib, 
selitrectinib and repotrectinib in complex with TRKA wild type, TRKA G595R, TRKA G667C and 
TRKA G667A mutants. Bound drugs (green sticks) and kinase residues 595 and 667 (colored 
spheres) are displayed. Chemical groups of larotrectinib, selitrectinib and repotrectinib that 
clash with mutant TRKA kinases are depicted as spheres for visualization purposes. (B) 
Radiometric in vitro kinase assays showing the kinase activity of TRKA wild type (WT), TRKA 
G595R and TRKA G667C single mutants and TRKA G595R/G667C and TRKA G595R/G667A 
double mutants treated with increasing concentrations of larotrectinib, selitrectinib and 
repotrectinib. Kinase activities are presented as % (mean±SD) considering an activity of 100% 
in the untreated kinases set as controls. IC50 calculated for each drug against the different 
kinases are indicated. Experiments were run in duplicates.  
 
Figure 3. Type II TRK Inhibitors Preferentially Bind to and Inhibit the Activity of TRKA 
xDFG Mutants  
(A) Representative models representing the most sampled conformations based on clustering 
the conformations generated during the Molecular Dynamics (MD) simulations showing 
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cabozantinib, foretinib and ponatinib in complex with TRKA G595R, TRKA G667C and TRKA 
G667A mutants; clustering was carried out using the K-clust algorithm based on the RMSD of 
the protein structures and only one major cluster (representing >90% of the conformations 
sampled) was seen for each complex. Bound drugs (green sticks) and kinase residues 595 and 
667 (colored spheres) are displayed. (B-D) Radiometric in vitro kinase assays showing the 
kinase activity of TRKA WT, TRKA G595R and TRKA G667C single mutants and TRKA 
G595R/G667C and TRKA G595R/G667A double mutants treated with increasing concentrations 
of cabozantinib (B), foretinib (C) and ponatinib (D). Kinase activities are presented as % 
(mean±SD) considering an activity of 100% in the untreated kinases set as controls. IC50 
calculated for each drug against the different kinases are indicated. Experiments were run in 
duplicates. (E) Determination of the binding affinity (Kd) of the type I inhibitor selitrectinib and 
the type II inhibitors cabozantinib and foretinib for the TRKA G667C mutant kinase in Microscale 
Thermophoresis (MST) assays. Kd fold changes are indicated (Average Kd of selitrectinib has 
been set as reference). Experiments were run in duplicates and P value was calculated using 
Student T-Test. (F) Representative models representing the most sampled conformations based 
on clustering the conformations generated during the Molecular Dynamics simulations showing 
the interactions between the Gly667/Cys667 - His648 in the inactive forms of TRKA WT (upper 
panel) and TRKA G667C (lower panel) kinases; clustering was carried out using the K-clust 
algorithm based on the RMSD of the protein structures and only one major cluster (representing 
>90% of the conformations sampled) was seen for each complex. Kinases are shown as 
cartoons (grey), the residues Gly/Cys667 and His648 are highlighted (green sticks) and the 
interactions (H-bound) between residues are shown as dashed lines (magenta). 
 
Figure 4. TRKA xDFG Mutated Bcan-Ntrk1 Mouse Glioma Cells Respond to Type II TRK 
Inhibitors   
(A-D) Strategy for the generation of knock-in isogenic Bcan-Ntrk1 glioma cells harboring the 
Trka G670C mutation is described. Sequences of gRNA and single strand donor template are 
shown. Cys670 (TGT) substitution is indicated (red). Silent mutations (green) in the point 
accepted mutation (PAM, in yellow) and gRNA seed sequence creating a new restriction site 
(green arrow head) to facilitate clones’ selection are also highlighted. CRISPR-Cas9 induced 
HDR event counts for G670C mutation in a pooled cell population was determined after FACS-
sorting by CRISPR-sequencing (B). RT-PCR using primers (black arrows) designed to detect 
the Bcan-Ntrk1 fusion transcript (C) or non-fused WT Ntrk1 transcript (D) was performed on 
total RNA. Sanger sequencing results of RT-PCR products are shown. Cell-Titer-Glo-based 
assays (E) and Western blot analyses (a representative experiment of a total of three 
independent replicates, F) performed on the Bcan-Ntrk1 WT and mutant clones showing the 
effect of type I (i.e., larotrectinib, selitrectinib and repotrectinib) and type II (i.e., cabozantinib, 
foretinib and ponatinib) TRK inhibitors on cell proliferation and TrkA-mediated downstream 
signaling. Proliferation assays are plotted as % survival normalized on control, untreated cells. 
Data of three independent experiments are plotted as mean±SD (E). (G) Representative 
Magnetic Resonance Imaging (MRI) scans of orthotopic mouse gliomas at baseline or 7 days 
after daily treatment with vehicle (upper panel) or cabozantinib (100mg/Kg; lower panel). (H) 
Quantification of tumor size in vehicle-treated control mice (n=3) and in cabozantinib-treated 
mice (n=4) at baseline and after 7 days of daily treatment. Volume was calculated using ImageJ 
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(in pixels). Each mouse was independently plotted. (I) Survival curves of vehicle and 
cabozantinib-treated mice. Note: mice received daily treatment until sacrifice. Mantel-Cox test 
was used to calculate significant differences between the two groups. A P value <0.05 was 
considered statistically significant. 
 
Figure 5. Type II Drugs Overcome Resistance to Second-generation TRK Inhibitors in 
Patient-derived Models 
Cell-Titer-Glo-based assays (A) and Western blot analyses (a representative experiment of a 
total of three independent replicates, B) performed on the LMNA-NTRK1, TRKA G595R and the 
LMNA-NTRK1, TRKA G595R/G667C double mutant primary colorectal cancer (CRC) cell lines 
showing the effect of type I (i.e., larotrectinib, selitrectinib and repotrectinib) and type II (i.e., 
cabozantinib, foretinib and ponatinib) TRK inhibitors on cell proliferation and TrkA-mediated 
downstream signaling. Proliferation assays are plotted as % survival normalized on control, 
untreated cells. Data of three independent experiments are plotted as mean±SD (A). In vivo 
efficacy of cabozantinib in xenografts established from the repotrectinib-resistant LMNA-NTRK1, 
TRKA G595R/G667C double mutant primary CRC (C) and in PDXs established from the 
selitrectinib-resistant tumor of Patient 1 (TPM3-NTRK1, TRKA G667C sarcoma; D) and Patient 
3 (LMNA-NTRK1, TRKA G595R/G667A CRC; E). 
 
Figure 6. Proposed Model 
Proposed model of sequential therapy in NTRK fusion-positive tumors. At diagnosis, tumors are 
mainly composed by WT TRK fusion-positive cells. The pool of kinase molecules in DFG-IN 
conformation is prevalent and patients are treated with type I, 1st-generation TRK inhibitors (first 
line therapy: i.e., larotrectinib). At progression, the most prevalent mechanism of on-target 
resistance is the emergence of TRK solvent front mutations that generate steric hindrance, thus 
compromising 1st-generation drugs activity. In cells harboring TRK solvent front mutations the 
pool of DFG-IN kinase molecules is still predominant, and patients are treated with type I 2nd-
generation TRK inhibitors (second line therapy: i.e., selitrectinib). At progression, emergence of 
TRK xDFG single and double mutations generates steric hindrance, compromising the binding 
of type I 2nd-generation TRK inhibitors, and induces the kinase to preferentially adopt its inactive 
DFG-OUT conformation, sensitizing to type II kinase inhibitors (proposed third line therapy). 
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